Miscellaneous dermatological conditions:
Indications for: VARITHENA
Treatment of incompetent great saphenous veins (GSV), accessory saphenous veins, and visible varicosities of the great saphenous vein system above and below the knee.
Adult Dosage:
See full labeling. For IV inj using ultrasound guidance, administered via a single cannula into the lumen of the target incompetent trunk veins or by direct inj into varicosities. Inject foam slowly (approx. 1mL/sec in the GSV and 0.5mL/sec in accessory veins or varicosities). Give up to 5mL per inj; max 15mL per treatment session. Repeat if necessary; separate sessions by a minimum of 5 days. Apply compression bandage or stocking. Have the patient walk for at least 10mins after treatment; monitor. Maintain compression for 2 weeks post-treatment.
Children Dosage:
Not established.
VARITHENA Contraindications:
Acute thromboembolic diseases.
VARITHENA Warnings/Precautions:
Do not inject intra-arterially. Must be experienced in venous procedures. Monitor for at least 10mins post-inj for anaphylaxis; treat appropriately if occurs. Increased risk of tissue ischemia in peripheral arteriosclerosis or thromboangiitis obliterans (Buerger’s Disease). Monitor for venous thrombosis post-treatment. Increased risk of thrombosis in patients with reduced mobility, history of DVT/PE, pregnancy, major surgery within 3mos, prolonged hospitalization. Pregnancy. Nursing mothers: consider interrupting breastfeeding up to 8hrs after dose.
VARITHENA Classification:
Sclerosing agent.
Adverse Reactions:
Pain/discomfort in extremity, infusion site thrombosis (retained coagulum), inj site hematoma or pain, thrombophlebitis superficial, extravasation; anaphylaxis (may be fatal).
Generic Drug Availability:
NO
How Supplied:
Convenience box—1 (w. canisters, transfer units, administration boxes); Bi-canister—1; Administration pack—1 (transfer unit, components)
